4D Molecular Therapeutics Inc (NASDAQ:FDMT) has a beta value of 2.87 and has seen 1.55 million shares traded in the last trading session. The company, currently valued at $138.45M, closed the last trade at $2.99 per share which meant it lost -$0.24 on the day or -7.43% during that session. The FDMT stock price is -965.89% off its 52-week high price of $31.87 and -5.69% below the 52-week low of $3.16. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.82 million shares traded. The 3-month trading volume is 804.22K shares.
The consensus among analysts is that 4D Molecular Therapeutics Inc (FDMT) is Buy stock at the moment, with a recommendation rating of 1.75. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight.
4D Molecular Therapeutics Inc (NASDAQ:FDMT) trade information
Sporting -7.43% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the FDMT stock price touched $2.99 or saw a rise of 18.97%. Year-to-date, 4D Molecular Therapeutics Inc shares have moved -46.32%, while the 5-day performance has seen it change -19.08%. Over the past 30 days, the shares of 4D Molecular Therapeutics Inc (NASDAQ:FDMT) have changed -27.78%. Short interest in the company has seen 5.03 million shares shorted with days to cover at 7.4.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 50.17% from current levels. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the current price level is -100.67% off the targeted high while a plunge would see the stock gain -100.67% from current levels.
4D Molecular Therapeutics Inc (FDMT) estimates and forecasts
The company’s shares have lost -72.39% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -9.89% over the past 5 years. Earnings growth for 2025 is a modest -20.38% while over the next 5 years, the company’s earnings are expected to decrease by -4.47%.
FDMT Dividends
4D Molecular Therapeutics Inc is expected to release its next earnings report on 2025-Feb-27 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
4D Molecular Therapeutics Inc (NASDAQ:FDMT)’s Major holders
Insiders own 3.89% of the company shares, while shares held by institutions stand at 103.16% with a share float percentage of 107.33%. Investors are also buoyed by the number of investors in a company, with 4D Molecular Therapeutics Inc having a total of 210.0 institutions that hold shares in the company. The top two institutional holders are RA CAPITAL MANAGEMENT, L.P. with over 5.1 million shares worth more than $107.01 million. As of 2024-06-30, RA CAPITAL MANAGEMENT, L.P. held 9.2221% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 4.9 million shares as of 2024-06-30. The firm’s total holdings are worth over $102.79 million and represent 8.8579% of shares outstanding.
